Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The hypothesis of the study is that the presence of (subclinical) gut inflammation at
baseline in patients with early active axial spondyloarthritis predisposes to a more severe
disease defined as more need to use anti-tumor necrosis factor α therapy and a shorter time
to relapse after stopping anti-tumor necrosis factor α therapy after obtaining sustained
clinical remission. Overall, the investigators hypothesize that subclinical gut inflammation
is an important predictor in therapy response and outcome. These data could provide better
insights into the complex interactions between gut and joint inflammation and guide the
physicians in the therapeutic approach.
Phase:
Phase 3
Details
Lead Sponsor:
University Ghent
Collaborators:
Merck Sharp & Dohme Corp. the Flanders Institute for Biotechnology